The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma
International Journal of Molecular Sciences · 21.01.2023 · 24 (3) · 2160
DOI: 10.3390/ijms24032160 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.01.2023. Verfasst von Florian N Loch und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 12203 Ber…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Berliner Krebsgesellschaft.
Abstract (Originalsprache)
Immune checkpoint therapy (ICT) has shown promising potential in the treatment of multiple solid tumors. However, the role of ICT in pancreatic ductal adenocarcinoma (PDAC) remains limited. Patterns of immune checkpoints (ICs) in PDAC represent the basis for establishing a potent ICT. The aim of this study is to create a profile of IC expression and its prognostic relevance in cancer cells of PDAC. Therefore, tumor cells from peripheral and central tissue microarray (TMA) spots from histologically confirmed PDAC of 68 patients after tumor resection were investigated in terms of expressions of TIM3, IDO, B7H4, LAG3, VISTA, and PD-L1 using immunohistochemistry. The presence of the respective ICs was compared to overall survival (OS). The presence of VISTA and PD-L1 significantly correlates with shorter OS (median OS: 22 months vs. 7 months and 22 months vs. 11 months, respectively, p < 0.05). For the presence of TIM3, IDO, B7H4, and LAG3, no difference in OS was observed (p > 0.05). The analysis of OS of combined subgroups for VISTA and PD-L1 (VISTA and PD-L1 neg., VISTA pos. and PD-L1 neg., VISTA neg. and PD-L1 pos., and VISTA and PD-L1 pos.) yielded overall statistical significance difference (p = 0.02). These results suggest that the presence of VISTA and PD-L1 is of prognostic relevance and potentially qualifies them as targets for ICT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 12203 Berlin, Germany.
- Department of Surgery, Park-Klinik Weißensee, 13086 Berlin, Germany.
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
- Berlin Institute of Health at Charité, Charitéplatz 1, 10117 Berlin, Germany.
- German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Partner Site Berlin, 69210 Heidelberg, Germany.
ORCID-Profile: Florian N Loch, Katharina Beyer, Christian Schineis, Mihnea P Dragomir, Simon Schallenberg
Förderung
- Berliner Krebsgesellschaft
Zitieren
APA
Loch, F. N., Kamphues, C., Beyer, K., Schineis, C., Rayya, W., Lauscher, J. C., Horst, D., Dragomir, M. P., & Schallenberg, S. (2023). The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 24(3), 2160. https://doi.org/10.3390/ijms24032160
Vancouver
Loch FN, Kamphues C, Beyer K, Schineis C, Rayya W, Lauscher JC, et al. The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences. 2023;24(3):2160. doi:10.3390/ijms24032160
BibTeX
@article{Loch2023,
author = {Loch, Florian N and Kamphues, Carsten and Beyer, Katharina and Schineis, Christian and Rayya, Wael and Lauscher, Johannes C and Horst, David and Dragomir, Mihnea P and Schallenberg, Simon},
title = {The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {3},
pages = {2160},
doi = {10.3390/ijms24032160}
}
EUVIMED